Bayer

Beleggen in aandelenbeurzen Europa: DAX, FTSE 100, CAC40, etc.

Gebruikersavatar
Banner
Premiummember
Premiummember
Berichten: 2007
Lid geworden op: 19 feb 2015 09:29
waarderingen: 1212
Contacteer:

Re: Bayer

Bericht door Banner »

charel01 liked last!
Specialisatie: dubbele account ontmaskeren.







Volg Beursig.com op Twitter en Facebook


Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 798
Lid geworden op: 30 mei 2018 21:25
waarderingen: 344
Contacteer:

Re: Bayer

Bericht door And its gone! »

BRIEF-Bayer Reaches Deals On Big Share Of 125,000 Roundup Weedkiller Suits - Bloomberg News
07:13 (25/05) - Bron: Reuters
May 25 (Reuters) -
* BAYER REACHES DEALS ON BIG SHARE OF 125,000 ROUNDUP
WEEDKILLER
SUITS - BLOOMBERG NEWS, CITING SOURCES
* BAYER IS LIKELY TO ANNOUNCE SETTLEMENTS, WHICH NEED
APPROVAL
FROM COMPANY’S SUPERVISORY BOARD, IN JUNE - BLOOMBERG NEWS

Source text: https://bloom.bg/3d19qFJ
Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))
charel01 liked last!
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, BCYC, YMAB, ZYME, SWTX, RCUS, TRIL, PASG.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 798
Lid geworden op: 30 mei 2018 21:25
waarderingen: 344
Contacteer:

Re: Bayer

Bericht door And its gone! »

Bayer has verbal agreement with some glyphosate claimants- Bloomberg
08:43 (25/05) - Bron: Reuters
FRANKFURT, May 25 (Reuters) - Bayer BAYGn.DE said on
Monday it had made progress seeking a settlement over claims its
glyphosate-based Roundup weedkiller causes cancer, after
Bloomberg reported the company reached a verbal agreement on
about 50,000 to 85,000 cases.
Bloomberg cited people familiar with the negotiations as
saying that the deals have yet to be signed and Bayer is likely
to announce the settlements in June.
"We've made progress in the Roundup mediation discussions
under the auspices of Ken Feinberg, but in keeping with the
confidentiality of this process, the company will not speculate
about settlement outcomes or timing," a Bayer spokesman said.
Bloomberg reported the overall number of U.S. cancer
lawsuits stood at 125,000, including tens of thousands being
held in abeyance by plaintiffs' lawyers under agreements with
Bayer.
Bayer said in April it has been served with cases in court
from 52,500 U.S. plaintiffs who blame Roundup and other
glyphosate-based weedkillers for their cancer, up from 48,600 in
February.

(Reporting by Ludwig Burger; editing by Thomas Seythal)
((ludwig.burger@thomsonreuters.com; +49 69 7565 1311; Reuters
Messaging: ludwig.burger.thomsonreuters.com@reuters.net))
charel01 liked last!
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, BCYC, YMAB, ZYME, SWTX, RCUS, TRIL, PASG.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 24353
Lid geworden op: 02 jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 13326
Contacteer:

Re: Bayer

Bericht door charel01 »

Friday - May 22, 2020
Not intended for U.S. and UK Media
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer

Berlin, May 22, 2020 – Bayer has submitted an application for marketing authorization for its precision oncology treatment larotrectinib to the Ministry of Health, Labor and Welfare (MHLW) in Japan. Larotrectinib is an oral TRK inhibitor that has been developed specifically to treat adults and children with locally advanced or metastatic solid tumors that have the rare genomic alteration called a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. The product is already approved in several countries under the brand name Vitrakvi™, including the U.S., Brazil, Canada and countries of the European Union (EU). Filings in other regions are underway or planned.

“With this submission, we are one step closer to providing patients and physicians in Japan with a highly selective treatment exclusively designed for adults and children with TRK fusion cancer, that has the potential to significantly improve treatment outcomes regardless of tumor type or patient age,” said Scott Z. Fields, M.D., Senior Vice President and Head of Oncology Development at Bayer's Pharmaceutical Division. “While cancers have previously been treated mainly in the body, larotrectinib was developed specifically to treat patients with TRK fusion cancer, regardless of where in the body the tumor originates. Larotrectinib represents an important advancement in the fight against this rare cancer, as it could replace costly treatment that is not targeted specifically to this cancer and does not have proven efficacy and safety in this patient population.”

The submission to the MHLW is based on clinical trial data from the Phase I trial of adult patients, the Phase II NAVIGATE trial in adult and adolescent patients and the Phase I/II pediatric SCOUT trial. In these trials, larotrectinib was investigated across more than 20 different histologies of solid tumors including lung, thyroid, melanoma, gastrointestinal stromal tumors, colon, cholangiocarcinoma, soft tissue sarcomas, salivary gland and infantile fibrosarcoma.

TRK fusion cancer is rare overall. It affects both children and adults and occurs in varying frequencies across various tumor types. TRK fusion cancer occurs when an NTRK gene fuses with another unrelated gene, producing an altered TRK protein. The altered protein, or TRK fusion protein, becomes constitutively active or overexpressed, triggering the activation of an intercellular signaling cascade. These TRK fusion proteins act as oncogenic drivers that fuel the spread and growth of the patients’ cancer, regardless of where it originates in the body.

About larotrectinib
Larotrectinib, a specific oral TRK inhibitor, was exclusively designed to treat tumors that have an NTRK gene fusion. The compound has demonstrated high response rates and durable responses with a favorable safety profile over three years in adults and children with TRK fusion cancer, including central nervous system (CNS) tumors. It has the largest dataset and longest follow-up data of any TRK inhibitor. The trials are still ongoing, with the latest dataset published in The Lancet Oncology and additional updates planned to be presented at upcoming scientific meetings.

Larotrectinib was approved in September 2019 in the European Union under the brand name Vitrakvi™ for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options. Vitrakvi has also received regulatory approval in additional markets, including the U.S, Brazil and Canada. Filings in other regions are underway or planned.

Following the acquisition of Loxo Oncology by Eli Lilly and Company in February 2019, Bayer has obtained the exclusive licensing rights for the global development and commercialization, including in the U.S., for larotrectinib and the investigational another TRK inhibitor selitrectinib (BAY 2731954) progressing through clinical development.

About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development.
Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Find more information at www.pharma.bayer.com
Go with the flow.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 798
Lid geworden op: 30 mei 2018 21:25
waarderingen: 344
Contacteer:

Re: Bayer

Bericht door And its gone! »

UPDATE 2-Bayer settles Roundup cancer lawsuits for up to $10.9 billion
19:12 (24/06) - Bron: Reuters
(Adds background on events leading up to settlement)
By Ludwig Burger
FRANKFURT, June 24 (Reuters) - Bayer AG BAYGn.DE agreed to
pay as much as $10.9 billion to settle thousands of U.S.
lawsuits claiming that its widely-used weedkiller Roundup caused
cancer after more than a year of talks, resolving litigation
that has pummeled the company's share price.
The German drugs and pesticides maker has come to terms with
about 75% of the 125,000 filed and unfiled claims overall, it
said in a statement on Wednesday of the deal to end legal
disputes it inherited with its $63 billion takeover of Monsanto
in 2018.
The settled cases over Roundup and other glyphosate-based
weedkillers account for about 95% of those currently set for
trial, it added.
"The Roundup settlement is the right action at the right
time for Bayer to bring a long period of uncertainty to an end,"
Bayer Chief Executive Werner Baumann said.
The company said it will make a payment of $8.8 billion to
$9.6 billion to resolve the current Roundup litigation -
including an allowance expected to cover unresolved claims - and
$1.25 billion to support a separate class agreement to address
potential future litigation.
Bayer said in February it did not need to write down
Monsanto's value in its books if it has to spend $10 billion on
a settlement, reflecting the average analyst estimate at the
time.
The company, whose management in April regained shareholder
support for its handling of the litigation process, has denied
claims that Roundup or its active ingredient glyphosate causes
cancer, saying decades of independent studies have shown the
product is safe for human use.
Monsanto began selling Roundup in 1974, and while the
formulation is no longer patent protected, Roundup remains
widely available.
Bayer has repeatedly said Roundup is safe and important to
farmers who use the herbicide in combination with the company's
genetically modified seeds.


(Reporting by Ludwig Burger; Editing by Edward Taylor, Maria
Sheahan and Bill Berkrot)
((ludwig.burger@thomsonreuters.com; +49 69 7565 1311; Reuters
Messaging: ludwig.burger.thomsonreuters.com@reuters.net))
Op naar de 100€ 8-)
Chukky2 liked last!
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, BCYC, YMAB, ZYME, SWTX, RCUS, TRIL, PASG.

Gebruikersavatar
Wimpie85
Premiummember
Premiummember
Berichten: 2726
Lid geworden op: 19 jan 2013 13:48
waarderingen: 1154
Contacteer:

Re: Bayer

Bericht door Wimpie85 »


LEVERKUSEN (AFN/BLOOMBERG/RTR) - Bayer is mogelijk nog lang niet verlost van juridische procedures rond het omstreden middel Roundup. Het chemiebedrijf sloot onlangs een megaschikking met Amerikanen die beweren kanker te hebben gekregen door de onkruidverdelger, maar volgens een rechter in Californië kunnen bepaalde onderdelen van die overeenkomst niet door de beugel.

In de schikking, waarmee in totaal 10,9 miljard dollar is gemoeid, zitten ook afspraken over de manier waarop toekomstige claims tegen Bayer wegens Roundup worden afgehandeld. Deze bepalingen moeten worden goedgekeurd door een rechter.

Het is hoogst onzeker dat die toestemming er ook daadwerkelijk komt, waarschuwt een Californische rechter nu in rechtbankdocumenten. Er is namelijk afgesproken dat een commissie van wetenschappers in de toekomst moet oordelen of glyfosaat, de werkzame stof in Roundup, kanker heeft veroorzaakt. Het is volgens de rechter "twijfelachtig" of zo'n overeenkomst juridisch stand houdt, want bij schadeclaims is het uiteindelijk aan de rechters of jury's is om te oordelen of Roundup kanker veroorzaakt.

Bayer heeft altijd volgehouden dat glyfosaat veilig is voor gebruik in de landbouw. Bij de schikking die in juni werd getroffen bekende het bedrijf dan ook geen schuld.

Volgens de Californische rechter is het ook de vraag of klagers in de toekomst wel gebonden willen zijn aan eerder gemaakte afspraken in de schikking, terwijl het onderzoek naar Roundup nog doorgaat. Later deze maand is er een zitting over de schikking.
And its gone! liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 798
Lid geworden op: 30 mei 2018 21:25
waarderingen: 344
Contacteer:

Re: Bayer

Bericht door And its gone! »

Bijgekocht aan 62.95€ :D gemiddelde nu 66.92€
Deze gaat vroeg of laat terug richting 100€ ondertussen kan je een mooi dividend opstrijken.
Alverman liked last!
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, BCYC, YMAB, ZYME, SWTX, RCUS, TRIL, PASG.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 24353
Lid geworden op: 02 jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 13326
Contacteer:

Re: Bayer

Bericht door charel01 »

Bayer nog altijd niet verlost van Roundup-zorgen

De even controversiële als dure miljardenovername van Monsanto blijft Bayer achtervolgen. Een Amerikaanse rechter vermindert weliswaar de boete die Monsanto, Bayer dus, moet ophoesten voor het overlijden van een tuinman, maar bevestigt wel dat de onkruidverdelger de kanker van de man veroorzaakt heeft.
Bron:"De Tijd"
Go with the flow.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 798
Lid geworden op: 30 mei 2018 21:25
waarderingen: 344
Contacteer:

Re: Bayer

Bericht door And its gone! »

Bayer loses California appeal of Roundup verdict, but damages are reduced
23:50 (20/07) - Bron: Reuters

By Jonathan Stempel and Tina Bellon

(Reuters) - Bayer AG <BAYGn.DE> failed to persuade a California appeals court to overturn a verdict favoring a school groundskeeper who claimed its Roundup weed killer caused his cancer but reduced the amount of damages by 74% to $20.5 million.

The decision by the California Court of Appeal came after a San Francisco jury had in August 2018 awarded $289.2 million to the plaintiff Dewayne Johnson for his non-Hodgkin's lymphoma, a sum later cut by the trial judge to $78.5 million.

Johnson's case is separate from Bayer's agreement on June 24 to pay up to $10.9 billion to settle nearly 100,000 lawsuits in the United States linking glyphosate-based Roundup to cancer.

If upheld, the verdict and payout could make it harder for Bayer to resolve lawsuits by other plaintiffs.

The German drugs and pesticides company inherited liability for the lawsuits when it bought Monsanto Co, which had produced Roundup, for $63 billion in 2018.

In a statement, Bayer called Monday's decision "a step in the right direction" but said it may appeal to the California Supreme Court, calling the verdict inconsistent with the evidence and the law.

Bayer has long said regulators have deemed glyphosate safe. "We continue to stand strongly behind the safety and utility of Roundup," the company said.

In its 86-page decision, the appeals court said Johnson offered "abundant" evidence that glyphosate, together with other ingredients in Roundup products, caused his cancer.

But it said the payout must be reduced because California law did not afford damages for a shortened life expectancy.

Johnson's lawyer R. Brent Wisner called the decision another major victory for his client, who is known as Lee, despite the reduced damages.

"That Lee will not live an entire life with his wife and children should be compensable," he said. "Hopefully, when this issue gets before the California Supreme Court, we can change this irrational law."

(Reporting by Jonathan Stempel and Tina Bellon in New York; Editing by Lisa Shumaker)
Schadevergoeding van 289 miljoen $ naar 20 miljoen $.
Nu nog eens naar Supreme Court, het blijft als een schaduw boven Bayer hangen.
De koers blijft laag imho, en het dividendrendement hoog.
NewB76 liked last!
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, BCYC, YMAB, ZYME, SWTX, RCUS, TRIL, PASG.

Gebruikersavatar
Alverman
Forum gebruiker
Forum gebruiker
Berichten: 205
Lid geworden op: 15 okt 2018 19:39
waarderingen: 102
Contacteer:

Re: Bayer

Bericht door Alverman »

charel01 schreef:
21 jul 2020 07:42
Bayer nog altijd niet verlost van Roundup-zorgen

De even controversiële als dure miljardenovername van Monsanto blijft Bayer achtervolgen. Een Amerikaanse rechter vermindert weliswaar de boete die Monsanto, Bayer dus, moet ophoesten voor het overlijden van een tuinman, maar bevestigt wel dat de onkruidverdelger de kanker van de man veroorzaakt heeft.
Bron:"De Tijd"
We hebben het al veel gezegd maar zo'n beoordeling kan niet overgelaten worden aan een volksjury. De advocaten zullen wel goed in hun handen wrijven bij deze lange aansleep. Triestige evolutie.
And its gone! liked last!


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie